The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt production of their knockoff versions of diabetes drug Mounjaro and obesity treatment Zepbound.

During the shortage, compounders have suddenly thrived, flooding the market with their lower-cost copycats to meet the booming demand for Lilly and Novo Nordisk’s weight loss treatments.

With the FDA move, however, state-licensed pharmacies will be required to stop manufacturing these therapies by Feb. 18.

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt production of their knockoff versions of diabetes drug Mounjaro and obesity treatment Zepbound.

During the shortage, compounders have suddenly thrived, flooding the market with their lower-cost copycats to meet the booming demand for Lilly and Novo Nordisk’s weight loss treatments.

With the FDA move, however, state-licensed pharmacies will be required to stop manufacturing these therapies by Feb. 18.